Aviceda Therapeutics moved to wind down after a Phase 2 failure for its geographic atrophy program, according to a person familiar with the decision. The company had been planning a Phase 3 step despite the mid-stage setback, underscoring how quickly clinical and regulatory momentum can reverse in late retinal pipelines.